Get all premium features to the best stock analysis tool

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Needham 25th Annual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am Eastern Time (ET). 2026 Bloom Burton & Co. Healthcare Investor Conference: Zymework's management will participate in one-on-one meetings and present on April 21 in Toronto, ON.

VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. “We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR,” said Ken Galbraith, Chair, Chief Executive Officer, and Interim Chief Financial Officer of Zymeworks.

VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, CA.

Zymeworks Inc. (ZYME) reported weak Q4 results, highlighting the volatility of its milestone-driven revenue model and underscoring execution risk ahead of commercialization. Despite top-line misses, ZYME improved FY25 profitability, narrowed net loss by 34%, and maintained strong liquidity with $270.6 million in cash and equivalents. The $250 million royalty-backed financing with Royalty Pharma extends ZYME's cash runway beyond 2028, reducing dilution risk but increasing dependence on Ziihera's commercial success.

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).